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Introduction:  Trials  demonstrate  signiﬁcant  clinical  beneﬁt  in  patients  receiving  therapeutic  hypothermia
(TH)  after  cardiac  arrest.  However,  incidence  of  mortality  and  morbidity  remains  high  in  this  patient
group.  Rapid  targeted  brain  hypothermia  induction,  together  with  prompt  correction  of  the underlying
cause  may  improve  outcomes  in these  patients.  This  study  investigates  the  efﬁcacy  of Rhinochill®, an
intranasal  cooling  device  over  Blanketrol®, a surface  cooling  device  in inducing  TH  in cardiac  arrest
patients  within  the  cardiac  catheter  laboratory.
Methods:  70  patients  were  randomized  to TH  induction  with  either  Rhinochill® or Blanketrol®. Primary
outcome  measures  were  time  to  reach  tympanic  ≤34 ◦C  from  randomisation  as  a surrogate  for brain
temperature  and  oesophageal  ≤34 ◦C from  randomisation  as  a measurement  of  core  body  temperature.
Secondary  outcomes  included  ﬁrst  hour  temperature  drop,  length  of stay  in  intensive  care  unit,  hospital
stay,  neurological  recovery  and all-cause  mortality  at hospital  discharge.
Results:  There  was  no  difference  in  time  to  reach  ≤34 ◦C between  Rhinochill® and  Blanketrol® (Tympanic
≤34 ◦C,  75  vs. 107  mins;  p =  0.101;  Oesophageal  ≤34 ◦C,  85 vs.  115  mins;  p  =  0.151).  Tympanic  temperature
dropped  signiﬁcantly  with  Rhinochill® in the ﬁrst hour  (1.75  vs. 0.94 ◦C;  p < 0.001).  No  difference  was
detected  in any  other  secondary  outcome  measures.  Catheter  laboratory-based  TH induction  resulted  in
a survival  to hospital  discharge  of 67.1%.
Conclusion:  In this  study,  Rhinochill® was  not  found  to be  more  efﬁcient  than  Blanketrol® for  TH  induction,
although  there  was  a  non-signiﬁcant  trend  in  favour  of  Rhinochill® that  potentially  warrants  further
investigation  with  a larger  trial.
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1,2. Retrospective registry data demonstrated that delays in ther-
apeutic hypothermia (TH) induction increases mortality 3,4. More
recent data from a large randomised trial have shown no difference
in outcomes when comparing targeted temperature management
(TTM) at 36 or 33 ◦C, suggesting the possibility that, prevention of
fever following cardiac arrest could be an important mechanism by
which neurological injury can be prevented 5. However, in this lat-
est study, delays in initiation of cooling (mean 130 min) and time to
reach 34 ◦C (mean 5 h) could have offset any potential beneﬁt that
TTM at 33 ◦C could offer in comparison to 36 ◦C 5,6.
Irrespective of whether methods are employed to reduce core
body temperature or to prevent systemic pyrexia, the mortality rate
and risk of permanent and disabling brain injury remains high in
this patient group. In the TTM trial 5, more than 50% patients in
both treatment groups died or had poor neurological function at
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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Fig. 1. An illustration of the Rhinochill device and its components.
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region to allow arterial access if needed for coronary intervention.
Unlike the Rhinochill® device, the Blanketrol® cooling machine80 day follow up. The alarming rates of morbidity and mortality
ssociated with cardiac arrest provide a large incentive for research
nto novel methods of treating this important group of patients.
In practice, several modalities of hypothermia induction exist
ncluding cold saline infusion 7, surface blankets 8 and endovascu-
ar cooling 9. Earlier studies indicated that targeted brain cooling
s more important in cerebral protection than whole body cool-
ng 10 and associated with lesser side effects 11. Rhinochill® is a
ortable, intranasal cooling system that is capable of rapid tar-
eted brain cooling (Fig. 1), as demonstrated in jugular venous
emperature recordings in animal models 12. Thus, it may  be able to
educe the risk of neurological injury associated with cardiac arrest
,10,13. In addition to its innovative mode of action, its portability
llows it to be applied to patients in conﬁned spaces and to be used
hilst transferring patients either from the ﬁeld to the hospital, or
etween different departments within the hospital.
Coronary artery disease is the most common cause of cardiac
rrest 14,15 and it is becoming increasingly common for these
atients to be brought directly to heart attack centres (HAC)
ith cardiac catheter laboratory facilities for emergency percuta-
eous coronary intervention (PCI). There is strong evidence that an
ggressive invasive approach combining emergency PCI and TH in
hese patients results in better outcomes 16.
In this randomised study, we test the hypothesis that
hinochill® device is more efﬁcient in TH induction than surface
ooling Blanketrol® for cardiac arrest patients presenting to a HAC,
n whom an underlying coronary etiology is suspected.
ethods
tudy design
Early targeted brain cooling in the cardiac catheterisation lab-
ratory following cardiac arrest (COOLCATH) was designed as a
ingle centre, prospective, open labelled, randomised controlled
linical trial to compare the efﬁciency of Rhinochill® intranasal
ooling device 17 in TH induction to our standard surface-cooling
rotocol with the Blanketrol® III device 18. The study received
thical approval from the National Research Ethics Service (Ref:
2/EE/0472). An independent data and safety monitoring commit-
ee reviewed the data and performed a comprehensive interim
nalysis. An independent data monitor performed regular data
hecks to ensure accuracy and completeness of data collection and
trict adherence to the study protocol.n 97 (2015) 61–67
Patients
74 adult patients suffering cardiac arrest, irrespective of any
speciﬁc initial presenting heart rhythm with return of sponta-
neous circulation (ROSC) after resuscitation were enrolled between
January 2013 and November 2014. The main exclusion criteria were
cardiac arrest caused by trauma, head injury, massive haemor-
rhage, patients without a deﬁnitive airway and patients who  were
already hypothermic on arrival (< 34 ◦C) (Appendix 1.1). As eligible
patients were unconscious on admission, initial written informed
consent was  obtained from a legal surrogate in accordance with
the Helsinki declaration 19. However, if the patient made sufﬁcient
neurological recovery and demonstrated mental capacity, a further
informed consent was obtained from the patient.
Randomisation
Patients were admitted directly to the HAC by the ambulance
crew, bypassing the local emergency department for emergency
catheter laboratory-based diagnostics and therapies. Patients ful-
ﬁlling the selection criteria were enrolled and randomised (by
allocation of a random-sealed envelope) in the cardiac catheter lab-
oratory to receive TH induction by either Rhinochill® or Blanketrol®
III cooling blanket in a 1:1 manner. Randomisation was pre-
performed by the local research and development ofﬁce using a
computer-generated assignment sequence dictating envelope allo-
cation.
Trial intervention
Baseline tympanic temperatures were recorded immediately
after randomisation as a surrogate for brain temperature and an
oesophageal temperature probe inserted at the earliest opportu-
nity to measure core body temperature in both treatment arms.
The oesophageal temperature recordings were taken to investi-
gate if there was  simultaneous drop in core body temperature. Both
tympanic and oesophageal temperatures were measured during TH
induction every 10 min  up to 5 h. It was not in our study protocol
to administer any additional TH-inducing agent and therefore, no
cold intravenous saline was given to patients in either group.
Rhinochill® 17
The RhinoChill® is the only CE-marked intranasal evapora-
tive cooling system 20 that is capable of inducing TH in cardiac
arrest patients. In patients randomised to the Rhinochill® group,
TH was  initiated in the cardiac catheter laboratory by advancing
the intranasal cannulae into each nostril, and switching on the
Rhinochill® device to deliver cold vapour into the nasal cavity. The
cooling continued throughout the initial induction period, during
PCI if performed, and patient transfer to the intensive care unit
(ICU), where maintenance cooling by conventional Blanketrol® III
could be commenced and Rhinochill® discontinued when the core
temperature reached ≤ 34 ◦C.
Blanketrol® cooling system 18
Patients allocated to Blanketrol® arm received TH induction in
the catheter laboratory by application of surface cooling blankets
covering the whole body but sparing a small area in the femoralneeded to be switched off during patient transfer from the catheter
laboratory to the ICU.
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Table  1
Baseline Characteristics of patients in each group before trial intervention Values
are presented as mean (standard deviation) and n (%); p > 0.05 for all comparisons.
Blanketrol Rhinochill
Age−mean (SD) 62.1 (12.5) 63.5 (12.3)
Male sex–n (%) 26 (74.3) 30 (85.7)
Body Surface Area−mean (SD) in m2 1.93 (0.29) 2.03 (0.22)
Cardiac History−n (%) 9 (25.7) 16 (45.7)
Bystander CPR−n (%) 22 (62.9) 24 (68.6)
Ventricular ﬁbrillation−n (%) 33 (94.3) 32 (91.4)
Time of untreated cardiac arrest−mean
(SD) in mins
5.06 (11.7) 2.83 (4.7)
Recurrence of cardiac arrest−n (%) 13 (37.1) 16 (45.7)
Shocks−mean (SD) 2.89 (2.23) 3.88 (4.56)
Median Time to ROSC from cardiac arrest
in mins (IQR)
21 (15−35) 20 (10−36)
Percutaneous intervention−n (%) 24 (68.6) 19 (54.3)
Inotropes−n  (%) 12 (34.3) 10 (28.6)
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tIntra-aortic balloon pump−n (%) 12 (34.3) 12 (34.3)
Mean 1st Tympanic temperature (◦C) 35.3 (0.80) 35.3 (1.0)
Mean 1st Oesophageal temperature (◦C) 35.3 (0.70) 35.1 (1.0)
eneral patient management
Patients in both intervention arms were maintained at <34 ◦C
or 24 h with active sedation and protected airway manage-
ent. The trust protocol for active sedation (Propofol infusion
t 0.3−4.0 mg/kg/hr, Morphine Sulphate infusion at 1−2 mg/hr)
nd shiver prevention (Atracurium at 5 mg/hr) was  followed
or all enrolled patients. After the maintenance phase (24 h),
atients were gradually rewarmed to 36 ◦C in hourly increments
f 0.25–0.5 ◦C and sedation weaned to allow the patients to regain
onsciousness. If patients were in cardiogenic shock, intra-aortic
alloon pumps were inserted at the discretion of the treating physi-
ian in the cardiac catheter laboratory and inotropes infusion was
dministered in the ICU (Table 1).
utcome measures
rimary outcomes
Primary outcome measures were time to reach tympanic ≤34 ◦C
rom randomisation as a surrogate for brain temperature and
esophageal ≤34 ◦C from randomisation as a measurement of core
ody temperature.
econdary outcomes
Secondary outcomes included rate of cooling in the ﬁrst hour,
ength of stay in ICU, hospital stay, neurological recovery and all-
ause mortality at hospital discharge. The neurological assessment
as made using the cerebral performance category (CPC) scale 21.
he CPC scale ranges from 1 to 5, with 1 indicating an excellent
ecovery and 5 signifying brain death (Appendix 1.2).
Adverse events were reported and documented as either related
o the study intervention or related to the presenting medical con-
ition by the safety monitoring committee. Decisions relating to
atient care, other than the method of TH induction, such as with-
rawal of active treatment, were taken at the discretion of the
reating physician, who was blinded to the trial intervention. Initial
emperature data collection and progress of patients’ health were
onitored daily by the research team, who were not blinded due
o the nature of the study intervention. If patients were discharged
rom hospital within 30 days, then a telephone call was made to
scertain the patient’s status.tatistics
Statistical analysis was conducted in a modiﬁed intention
o treat population, deﬁned as all randomly assigned patientsn 97 (2015) 61–67 63
excluding those withdrawn from the study due to a delayed diag-
nosis or meeting one of the exclusion criteria. Descriptive statistics
are presented for continuous, as well as categorical variables as
mean (standard deviation) and tabulated by treatment. Analyses
were performed using the computer program R 22. The time taken
to reach target temperature (≤34 ◦C), duration of ventilation hours,
ICU stay and hospital stay were expected to have a non-normal dis-
tribution and so the means for the two groups were compared using
a two-sample permutation t-test with bootstrap 95% conﬁdence
limits for the difference between the means. The CPC between the
two groups were described in a contingency table and compared
using Fisher’s exact test. For statistical signiﬁcance, a p-value of
0.05 was  adopted. The analysis was performed by an independent
statistician.
Results
Patients
A total of 120 cardiac arrest patients were screened for enrol-
ment, out of which 46 patients were excluded for not meeting
selection criteria. All 74 eligible patients were enrolled, of which 37
were allocated to Blanketrol® and 37 were allocated to Rhinochill®
therapy.
Exclusions after enrolment: There were four exclusions from
patients enrolled: two patients in the Blanketrol® arm and one
patient in the Rhinochill® arm were found to have sub-arachnoid
haemorrhage on subsequent CT scan following randomisation
and one patient in the Rhinochill® arm was already hypothermic
(≤34 ◦C) at randomisation (Fig. 2).
Coronary angiography: Although, all patients were received
and enrolled in the cardiac catheter laboratory, four patients allo-
cated to Rhinochill® did not undergo coronary angiography at the
physician’s discretion (two patients had pre-existing three vessel
coronary artery disease, not amenable for PCI and two patients were
haemodynamically unstable for catheter laboratory admission).
One patient randomised to Blanketrol therapy did not undergo
coronary angiography as the admitting physician reported that
there was  no clear ST elevation on ECG.
Adverse events
There were no trial related adverse events or serious adverse
events in patients randomised to Blanketrol®. One patient allocated
to Blanketrol® TH induction was withdrawn prematurely due to
development of retroperitoneal bleed, unrelated to trial interven-
tion and required surgical intervention equating to 97% success rate
of TH device application in this group.
There were four trial related adverse events in patients treated
with Rhinochill®—two patients (5.7%) experienced epistaxis and
two patients (5.7%) experienced white nose tip. These adverse
events recovered without any further intervention upon termina-
tion of Rhinochill® induction phase. Four patients randomised to
Rhinochill® therapy required early termination of trial intervention
and crossed over to Blanketrol® for TH induction and maintenance
equating to a success rate of 89% for device employment within
the catheter laboratory in this group. Only one of these incidents
was trial related: epistaxis (n = 1) and the others were unrelated
events: acute respiratory distress (pulmonary oedema and peri-
arrest gastric aspiration; n = 2) and technical difﬁculties with device
(n = 1).There were no exclusions due to withdrawal of consent. All
enrolled patients were followed up according to trial protocol. The
two groups had similar baseline characteristics prior to randomi-
sation including the mean ﬁrst temperature recordings (Table 1).
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Fig. 2. Flow of participants from recruitment to analysis.
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H induction
From randomisation, the mean time to target tympanic tem-
erature (≤34 ◦C) as a surrogate for brain temperature was  75 min
median 45; range: 0−240) in the Rhinochill® arm in comparison
ith 107 min  in the Blanketrol® arm (median 70; range: 0−366)
p = 0.101).
The mean time to oesophageal temperature (≤34 ◦C) was 85 min
median 50; range 0−270) in the Rhinochill® arm compared with
15 min  (median 80; range 10−366) in the Blanketrol® arm from
andomisation (p = 0.151).
The results are summarised in Table 2 and shown in graphical
orm in Fig. 3.
econdary outcomes
In the ﬁrst hour of cooling, the tympanic temperature dropped
igniﬁcantly more quickly in the Rhinochill® arm than the
lanketrol® arm (1.75 vs. 0.94 ◦C; p < 0.001) (Fig. 3). There were
o signiﬁcant differences between length of ventilation hours, stay
n ICU, duration of hospital stay, and CPC one to two  outcomes
etween the two groups (Table 3).There were no signiﬁcant differences in survival to hospital dis-
harge between patients treated with Rhinochill® and Blanketrol®
herapy (65.7 vs. 68.6%, respectively, Table 3). This equates to a
ombined survival to hospital discharge of 67.1%.Discussion
Rhinochill® did not achieve statistical superiority in achieving
target temperature (≤34 ◦C) from randomisation, although there
is trend towards faster cooling with Rhinochill® therapy in both
tympanic and oesophageal temperature recordings as surrogate
for brain temperature and core body temperature, respectively.
Rhinochill® induction achieved statistically signiﬁcant tympanic
temperature reductions compared with Blanketrol® during the ﬁrst
hour of cooling suggesting more rapid and focused brain cooling.
(Table 3a)
The cooling times in both groups in this trial are impressive
when one compares to other trials carried out in this ﬁeld 2,5,7.
While we  have shown that an aggressive cooling strategy in the
catheter laboratory can result in a mean time to target tym-
panic temperature (≤34 ◦C) of 75 and 85 min with Rhinochill® and
Blanketrol®, respectively, there is still a 1−2 h period in the ﬁeld
and during transfer to the HAC where no brain cooling is initiated.
It may be that even earlier and even more aggressive targeted brain
cooling is required to show a signiﬁcant survival and neurologi-
cal improvement when compared with TTM. The PRINCESS trial
that is currently recruiting in Europe will help to answer this ques-
tion, as to whether pre-ROSC-targeted brain cooling can improve
cardiac arrest outcomes 23 and if successful, a future large-scale
randomised controlled study can be designed to compare intra-
arrest cooling and TTM protocol at 36 ◦C. (Table 3b)
Irrespective of the study intervention, COOLCATH demonstrates
a combined survival rate of over 67.1% at hospital discharge in both
S. Islam et al. / Resuscitation 97 (2015) 61–67 65
Table  2
Temperature data of the two groups: comparison of group means using two-sample permutation t-tests and bootstrap 95% conﬁdence limits.
Blanketrol Rhinochill Residual standard deviation
Mean Mean
Outcome measure
Time to tympanic temp ≤34 ◦C from randomisation 107.2 75.2 78.4
(n  = 32) (n = 33)
Time  to oesophageal ≤34 ◦C from randomisation 114.9 84.7 83.4
(n  = 33) (n = 32)
Tympanic temperature drop (◦C in ﬁrst hour) 0.935 1.75 0.897
(n  = 31) (n = 30)
Oesophageal temperature drop (◦C in ﬁrst hour) 0.904 1.148 0.573
(n  = 24) (n = 23)
Tympanic temperature slope (◦C in ﬁrst hour) -0.808 -1.615 0.867
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Oesophageal temperature slope (◦C in ﬁrst hour) -0.823
(n  = 35
roups, which is better than previously reported trials with similar
tudy designs 1,3,13. Sub-group analysis of patients presenting with
nitial shockable rhythm demonstrates a combined survival rate
as 75.3% which is favourable to previously reported data 7,8. This
ould be partly explained by simultaneous coronary intervention
nd early TH induction in the catheter laboratory, providing max-
mal myocardial salvage and neuro-protection in these patients.
H has been shown to have beneﬁcial effects on left ventricular
yocardial salvage in animal models of coronary artery occlusion
Fig. 3. Medians and ranges of outcome m(n = 35)
-1.21 0.829
(n = 32)
and reperfusion 24–26. Studies of TH in humans presenting with ST
elevation myocardial infarction (STEMI) have so far not established
signiﬁcant clinical beneﬁt 27–29. However, a recent multi-centre
randomised controlled trial 27 demonstrated a 33% reduction in
infarct size if TH was administered within 4 h of symptom onset in
patients with anterior STEMI, and also a reduction in incidence of
heart failure was noted in this group. (Table 3c)
Our trial has limitations. In retrospect, the sample size was not
sufﬁcient to detect a difference in the primary outcome measure. A
easures for each Study arm limits.
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Table  3a
Length of ventilation hours, duration of stay in ICU and hospital: comparison of group means using two-permutation t-tests and bootstrap 95% conﬁdence limits.
Outcome measure Blanketrol
mean
Rhinochill
mean
Residual standard deviation Difference: p-value
Length of ventilation (hours) 100.7
(n = 35)
218
(n = 35)
280.9 117.2 0.079
(-12.3, 254.2)
Length of ICU stay (hours) 145.6
(n = 34)
210.5
(n = 34)
169.3 64.9 0.122
(-14.5, 142.1)
Length of hospital stay (hours) 447.9
(n = 35)
508.9
(n = 35)
656.9 61 0.709
(-239.9, 381.9)
Table 3b
Cerebral performance category (CPC): comparison of percentages using Fisher’s Exact Test.
Outcome category Blanketrol Rhinochill Difference: Rhinochill – Blanketrol (95% conﬁdence limits) p-value
CPC (1-2) at ICU discharge 51.40% 45.70% 
(18/35) (16/35) 
CPC (1-2) at hospital discharge 57.10%(20/35) 54.30%(19/35) 
Table 3c
Comparison of survival to hospital discharge between two  groups.
Blanketrol Rhinochill Overall
Survival to hospital discharge 68.60% 65.70% 67.10%
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2  Moderate disability
3  Severe disability(24/35) 23/35 (47/70)
ost hoc calculation would suggest that a minimum of 192 patients
ould be required to have 80% power to detect a statistically
igniﬁcant difference in the time to reach ≤34 ◦C from randomi-
ation. Secondly, TH was only initiated when the patients were
dmitted to hospital but ROSC was usually achieved at the site of
ardiac arrest. Therefore, valuable time is lost during patient trans-
er, when no TH is offered to patients, and neurological damage
s inﬂicted. Thirdly, tympanic temperature recordings were taken
s a surrogate marker of brain temperature. Whilst earlier stud-
es reported a close correlation between tympanic temperature
ecordings and brain temperature 30, other studies have challenged
his concept 31. Magnetic resonance spectroscopy 32 and other
ovel methods of measuring brain temperature can be explored
n future trials. Fourthly, the nature of the intervention used meant
hat the trial was  unblinded to some of the treating medical team,
hich may  introduce some bias. Finally, patients were followed up
o hospital discharge, which may  not give us adequate information
egarding neurological recovery and mortality following a cardiac
rrest.
onclusions
Rhinochill® can be applied safely in the cardiac catheter labo-
atory for the vast majority of patients undergoing emergency PCI
ollowing cardiac arrest and during transfer to ICU. The combina-
ion of aggressive catheter laboratory cooling and urgent coronary
evascularisation in a specialist cardiac unit resulted in a mean
verall trial survival rate to hospital discharge of 67.1%. In this
tudy population, Rhinochill® did not achieve better efﬁciency in
H induction compared with Blanketrol® surface cooling and there
ere no differences in clinical outcomes between the two groups.
here is, however, a non-signiﬁcant trend in favour of Rhinochill®
hat potentially warrants further investigation with a larger trial. If
uch a trial was to show a statistically signiﬁcant advantage, then
uture research would be required to determine whether earlier
nd more rapid targeted brain hypothermia induction improves
eurological outcome and mortality in patients presenting with
ardiac arrest.-5.7 0.811
(-27.5, 16.9)
-2.9 (-24.8, 19.5) 1
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Appendix A. Appendix
A.1. Patient Selection Criteria
Patient Inclusion Criteria
1) ≥ 18 years old
2) Post cardiac arrest with ROSC
3) Planning to receive therapeutic hypothermia as part of post-
cardiac arrest care
Patient Exclusion Criteria
1) Cardiac arrest caused by trauma, head injury, massive haemorrhage,
drug overdose, cerebrovascular accident, drowning, electric shock or
hanging.
2) Already hypothermic (<34 ◦C).
3)  Nasal obstruction preventing the insertion of a nasal catheter.
4)  Patients without established deﬁnitive airway.
5)  Do Not Attempt to Resuscitate (DNAR) orders.
6)  Known terminal illness (e.g. malignancy in the end stages).
7)  Known or obvious pregnancy.
8) Known coagulation disorder (except those induced by medication,
e.g. thrombolytics).
9) Known O2- dependency.
A.2. CPC Scale
CPC Scale Interpretation
1 Good cerebral performance or minor disability4 Coma or vegetative state
5 Brain death
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